Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study.
Bliuc D, Tran T, van Geel T, Adachi JD, Berger C, van den Bergh J, Eisman JA, Geusens P, Goltzman D, Hanley DA, Josse RG, Kaiser S, Kovacs CS, Langsetmo L, Prior JC, Nguyen TV, Center JR; CaMOS Research Group.
Bliuc D, et al.
Osteoporos Int. 2019 Apr;30(4):817-828. doi: 10.1007/s00198-018-4806-0. Epub 2019 Jan 3.
Osteoporos Int. 2019.
PMID: 30607457